Study: Diabetes patients may do better with everolimus stents

04/7/2013 | Healio

Data on 968 diabetes patients who had percutaneous coronary intervention revealed those who used paclitaxel-eluting stents had higher thrombosis rates at six and 12 months and higher mortality at one year compared with those who were treated with everolimus-eluting stents. The findings appear in Catheterization and Cardiovascular Interventions.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA